	Application No.	Applicant(s)
Notice of Allowability	10/790,288	BERTHELETTE ET AL.
	Examiner	Art Unit
	Joseph Kosack	1626
	Јозерн Козаск	1020
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>IDS filed 19 November 2004</u> .		
2.  The allowed claim(s) is/are <u>1-15 and 17-25</u> .		
<ul> <li>3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have been received.</li> </ul>		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
<ol> <li>DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.</li> </ol>		
Attachment(s)	E Matico of Informal D	latent Application
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Dotice of Draftperson's Patent Drawing Review (PTO-948)</li> </ol>	<ul><li>5. ☐ Notice of Informal P</li><li>6. ☐ Interview Summary</li></ul>	
2. I Notice of Draitperson's Patent Drawing Review (P10-946)	Paper No./Mail Dat	le
<ol> <li>Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>11/19/2004</u></li> </ol>	7. 🛭 Examiner's Amendr	nent/Comment
4.   Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	

Application/Control Number: 10/790,288

Art Unit: 1626

#### **DETAILED ACTION**

Claims 1-25 are pending in the instant application.

## **Priority**

The claim to priority of US Serial Number 60/452,124 filed March 5, 2003 has been granted in the instant application.

### Information Disclosure Statement

The Information Disclosure Statement filed on November 19, 2004 has been considered fully by the Examiner.

#### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Raynard Yuro on September 19, 2006.

The application has been amended as follows:

In claim 11, line 2, delete "comprising" and insert ---selected from osteoarthritis, rheumatoid arthritis and chronic pain, comprising---.

In claim 13, line 2, delete "condition" and insert --- condition selected from osteoarthritis, rheumatoid arthritis and chronic pain---.

Delete claim 16.

Application/Control Number: 10/790,288

Art Unit: 1626

#### Reasons For Allowance

The present invention is drawn to compounds of the formula:

and its method of treating COX-2 mediated

conditions. The closest prior art teaches compounds of the formula:

which does not anticipate or adequately

suggest the alkyl linkage between the ester and nitroxy groups of the molecule.

Therefore, claims 1-15 and 17-25 are allowed.

# Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Kosack whose telephone number is (571)-272-5575. The examiner can normally be reached on M-F 5:30 A.M. until 2:00 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph M<sup>o</sup>Kane can be reached on (571)-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/790,288 Page 4

Art Unit: 1626

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Joseph Kosack Patent Examiner Art Unit 1626

Supervisory Patent Examiner

Art Unit 1626